medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2008, Número 5

<< Anterior Siguiente >>

Rev Mex Oftalmol 2008; 82 (5)


Actualidades en el tratamiento de la retinosis pigmentaria

Achar V, Zenteno JC

Idioma: Español
Referencias bibliográficas: 35
Paginas: 309-313
Archivo PDF: 29.49 Kb.


RESUMEN

La retinosis pigmentaria es la distrofia de retina de tipo hereditario más frecuente. La enfermedad es una causa común de ceguera irreversible y en la actualidad no se dispone de un tratamiento curativo. En los últimos años se han desarrollado varias estrategias terapéuticas encaminadas a disminuir la progresión del curso clínico de la enfermedad con resultados alentadores. En este artículo se revisan los avances logrados con tratamiento a base de vitaminas, transplante de retina, prótesis retinianas, terapia génica y terapia hiperbárica, entre otros.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Hims MM, Inglehearn CF. Retinitis pigmentosa: genes, proteins and prospects. Dev Ophthalmol 2003; 37:109-125.

  2. Stephen P. Daige, P, Lori S. Perspective on Genes and Mutations Causing Retinitis Pigmentosa. Arch Ophthalmol 2007; 125 (2):151-158.

  3. Berson EL, Sandberg MA, Hayes KC, Nicholson BWy cols. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol 1193; 111(6):761-772.

  4. Berson EL, Sandberg MA, Hayes KC, Nicholson BW y cols. Vitamin A supplementation for retinitis pigmentosa. Arch Ophthalmol 1993; 111(11):1456-1459.

  5. Berson EL. Treatment of Retinitis Pigmentosa with vitamin A. Digital J Ophthalmology 1998; 04(7) Disponible en www.djo.harvard.edu.

  6. Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C y cols. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol 2004; 122(9):1297-1305.

  7. Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C y cols. Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. Arch Ophthalmol 2004;122(9):1306-1314.

  8. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet 2006; 368 (9549):1795-1809.

  9. Yu TY, Acosta ML, Ready S, Cheong YL, Kalloniatis M. Light exposure causes functional changes in the retina: increased photoreceptor cation channel permeability, photoreceptor apoptosis, and altered retinal metabolic function. J Neurochem 2007; 103(2):714-724.

  10. Paskowitz DM, Duncan JL. Light and inherited retinal degeneration. Br J Ophthalmol 2006; 90(8):1060-6.

  11. Wang M, Tso MOM, Naash MI. Expression of a mutant opsin gene increases the susceptibility of the retina to light damage. Vis Neuroscience 1997; 1455-62.

  12. Hamel C. Retinitis pigmentosa. Orphanet J Rare Diseases 2006; 1(40).

  13. Berson EL. Light deprivation and retinitis pigmentosa. Vision Res 1980; 20 (12):1179-1184.

  14. Miyake Y, Horiguchi M, Yagasaki K. Light deprivation and retinitis pigmentosa Am J Ophthalmol 1990; 110(3):305-306.

  15. Vingolo EM, Pelaia P, Forte R, Rocco M, Giusti C, Rispoli E. Does hyperbaric oxygen (HBO) delivery rescue retinal photoreceptors in retinitis pigmentosa? Doc Ophthalmol 1999; 97(1):33-39.

  16. Stone J, Maslim J, Valter K, Hollander H. The influence of oxygen levels on the death and survival of photoreceptors. Retinal Degeneration in Degenerative Diseases of the retina 1996: 371–377.

  17. Vingolo EM, Rocco M, Grenga PG, Salvatore S, Pelaia P. Slowing the degenerative process, long lasting effect of hyperbaric oxygen therapy in retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol 2007; 246:93–98

  18. Otani A, Dorrel MI, Kinder K, Moreno SK, Nusinowitz S, Banin E. Rescue of retinal degeneration by intravitreally injected adult bone marrow derived lineage-negative hematopoietic stem cells. J Clin Invest 2004; 114(6):765-774.

  19. Kociok N. Can the injection of the patient’s own bone marrow-derived stem cells preserve cone vision in retinitis pigmentosa and other diseases of the eye? Graefes Arch Clin Exp Ophthalmol 2005; 243(3):187-188.

  20. Mezey E, Chandross KJ, Harta G, Maki RA, McKercher SR. Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow. Science 2000; 290 (5497):1779-1782.

  21. Zrenner E, Besch D, Bartz-Schmidt KU, Gekeler F y cols. Subretinal chronic multi-electrode arrays implanted in blind patients. Invest Ophthalmol Vis Sci 2006; 47:1538.

  22. Yanai DWJ, Mahadevappa M, Greenberg RJ, Fine I, Humayun MS. Visual performance using a retinal prosthesis in three subjects with retinitis pigmentosa. Am J Ophthalmol 2007; 143(5):820-827.

  23. Acland GM, Agirre GD, Ray J, Zhang Q, Aleman TS y cols. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 2001; 28:92-95.

  24. Acland GM, Aguirre GD., Bennett J, Aleman TS y cols. Longterm restoration of rod and cone vision by single dose rAAVmediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther 2005; 12:1072-1082.

  25. Weber M, Provost N, Conrath H, Folliot S, Briot D y cols. Recombinant adeno-associated virus serotype 4 mediates unique and exclusive long-term transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery. Mol Ther 2003; 7:774-778.

  26. Min SH, Molday LL, Seeliger MW, Dinculescu A y cols. Prolonged recovery of retinal structure/function after gene therapy in an Rs1h-deficient mouse model of x-linked juvenile retinoschisis. Mol Ther 2005; 12:644-651.

  27. Kairisalo M, Korhonen L, Blomgren K, Lindholm D. X-linked inhibitor of apoptosis protein increases mitochondrial antioxidants through NF-kappaB activation. Biochem Biophys Res Commun 2007; 364(1):138-144.

  28. Leonard KC, Petrin D, Coupland SG, Baker AN y cols. XIAP protection of photoreceptors in animal models of retinitis pigmentosa. PLoS ONE 2007; 2(3): 314.

  29. Bainbridge JW, Smith AJ., Barker SS, Robbie S y cols. Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med 2008; 358(21): 2282-2284.

  30. Radtke ND, Aramant RV, Seiler MJ, Petry HM, Pidwell D. Vision change after sheet transplant of fetal retina with retinal pigment epithelium to a patient with retinitis pigmentosa. Arch Ophthalmol 2004; 122(8):1159-1165.

  31. Ghosh F, Engelsberg K., English RV, Petters RM. Long-term neuroretinal full-thickness transplants in a large animal model of severe retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol 2007; 245(6):835-846.

  32. Radtke ND, Aramant RV, Petry HM, Green PT, Pidwell DJ, Seiler MJ. Vision Improvement in Retinal Degeneration Patients by Implantation of Retina Together with Retinal Pigment Epithelium. Am J Ophthalmol 2008; en prensa.

  33. Samardzija M, Wenzel A., Thiersch M, Frigg R, Remé C, Grimm C. Caspase-1 ablation protects photoreceptors in a model of autosomal dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci 2006; 47(12):5181-5190.

  34. Sahel JA. Saving cone cells in hereditary rod diseases: a possible role for rod-derived cone viability factor (RdCVF) therapy. Retina 2005; 25(8 Supl):S38-S39.

  35. Boatright JH, Moring AG, McElroy C, Phillips MJ, Do VT y cols. Tool from ancient pharmacopoeia prevents vision loss. Mol Vis 2006; 12:1706-1714.




2020     |     www.medigraphic.com